Annexon, Inc. Common Stock
ANNXStock
$5.89+112.64%52W
Market Cap$965.03M
P/E—
Div yield—
Beta1.17
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)0.15%
Price vs S&P 500 (4W)20.01%
VGM Score57.01
Market Capitalization$965.03M
Earnings Surprise History
Q1 26-0.23est. -0.29
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.19
4.19
4.19
4.12
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANNXAnnexon, Inc. Common Stock | — | — | C | $5.89 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Annexon Inc is a clinical-stage biopharmaceutical company developing C1q inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company's platform technology targets the classical complement pathway across multiple disease areas affecting the body, brain, and eye. Its pipeline includes product candidates ANX005, ANX007, ANX009, and ANX1502 in development.